WO2014049370A1 - Disinfectant formulation - ms71 - Google Patents
Disinfectant formulation - ms71 Download PDFInfo
- Publication number
- WO2014049370A1 WO2014049370A1 PCT/GB2013/052527 GB2013052527W WO2014049370A1 WO 2014049370 A1 WO2014049370 A1 WO 2014049370A1 GB 2013052527 W GB2013052527 W GB 2013052527W WO 2014049370 A1 WO2014049370 A1 WO 2014049370A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disinfectant formulation
- disinfectant
- formulation
- ammonium chloride
- coupon
- Prior art date
Links
- 239000000645 desinfectant Substances 0.000 title claims abstract description 133
- 239000000203 mixture Substances 0.000 title claims abstract description 123
- 238000009472 formulation Methods 0.000 title claims abstract description 122
- 239000000758 substrate Substances 0.000 claims abstract description 39
- 241000894006 Bacteria Species 0.000 claims abstract description 32
- 230000000249 desinfective effect Effects 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 26
- 229910001220 stainless steel Inorganic materials 0.000 claims description 22
- 239000010935 stainless steel Substances 0.000 claims description 22
- WSFMFXQNYPNYGG-UHFFFAOYSA-M dimethyl-octadecyl-(3-trimethoxysilylpropyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCC[Si](OC)(OC)OC WSFMFXQNYPNYGG-UHFFFAOYSA-M 0.000 claims description 20
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 244000005700 microbiome Species 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims 1
- 230000009467 reduction Effects 0.000 abstract description 17
- 238000012360 testing method Methods 0.000 description 27
- 239000002054 inoculum Substances 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 12
- 239000004744 fabric Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 9
- 239000007195 tryptone soya broth Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000006150 trypticase soy agar Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- 206010011409 Cross infection Diseases 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000012864 cross contamination Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000005574 cross-species transmission Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 238000011012 sanitization Methods 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 1
- VBUUATKGJOATLP-UHFFFAOYSA-N N-(5-piperidin-4-yl-1-propan-2-ylpyrazol-3-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C(C)(C)N1N=C(C=C1C1CCNCC1)NC1=NC=CC(=C1)C(F)(F)F VBUUATKGJOATLP-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 125000006182 dimethyl benzyl group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- -1 laminates Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- PZJJKWKADRNWSW-UHFFFAOYSA-N trimethoxysilicon Chemical group CO[Si](OC)OC PZJJKWKADRNWSW-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/12—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
Definitions
- the present invention relates to a disinfectant formulation, its use for disinfecting a substrate surface and a process for preparing such a disinfectant formulation.
- the present invention provides a long lasting continuous disinfectant formulation that achieves a Log reduction in the number of bacteria on the surface of at least 7.0 for 30 days.
- the present invention meets this need and solves the problem and thus helps combat the dangerous and growing risk of healthcare-associated infections and other surface-borne, touch-transferable infections.
- the present invention provides a high grade long -lasting continuous surface disinfectant that will become a key weapon in the fight against this ever-present risk. This is achieved by the disinfectant formulation of the present invention containing a combination of ingredients that unexpectedly provide a synergistic disinfectant effect.
- the disinfectant formulation of the present invention provides a disinfectant effect on a substrate surface longer than would have been expected.
- the disinfectant formulation of the present invention has been rigorously tested and vigorously proven to give not only immediate, but up to 30-day-long continuous pre- emptive deterrent action that can be verified - breaking an important link in the chain of infection. To be assured the same effectiveness and the same 24/7 protection that the present invention provides, surfaces would need to be disinfected with a conventional disinfectant formulation every time they were touched, even if they had only recently been disinfected.
- the invention provides a disinfectant formulation comprising 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride, and citric acid.
- the invention provides the use of a disinfectant formulation comprising 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2 i6) dimethyl benzyl ammonium chloride, and citric acid, for disinfecting a substrate surface.
- a method of disinfecting a substrate surface comprising applying to said substrate surface a disinfectant formulation comprising 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride, and citric acid.
- the disinfectant formulation is used to control the disinfectant formulation
- Staphylococcus aureus Methicillin-resistant Staphylococcus aureus (MRSA)
- VRE Vancomycin-resistant Enterococcus
- the invention provides a process for preparing a disinfectant formulation according to the first aspect of the invention comprising combining 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride, and citric acid
- fectant is used in line with its conventional meaning to refer to a substance that is applied to a non-living object (a substrate surface) to destroy microorganisms, e.g. bacteria, that may be present on that surface.
- the term is also intended to cover sanitization.
- the disinfectant formulation of the invention effectively reduces the number of bacteria inoculated onto a substrate surface. Furthermore, the product remains effective as a disinfectant for at least 30 days after it has been applied to the surface.
- One component of the disinfectant formulation of the present invention is 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, which is a quaternary ammonium antibacterial compound.
- 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride is known to exhibit disinfectant properties and inhibit
- 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride employed in the present invention may be in any form.
- any commercially available form of it may be employed in the present invention. This includes condensed or diluted forms.
- 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride is commercially available.
- an effective amount of 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride is employed in the disinfectant formulation of the present invention.
- An effective amount may represent from about o.i to about io% by weight based on the total weight of the disinfectant formulation.
- the disinfectant formulation of the present invention comprises 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride in an amount from about o.i to about 5.0% by weight based on the total weight of the disinfectant formulation, more preferably from about 0.5 to about 2.0% by weight, even more preferably from about 0.8 to about 1.0% by weight based on the total weight of the disinfectant formulation.
- a further component of the disinfectant formulation of the present invention is alkly(Ci2 i6) dimethyl benzyl ammonium chloride, which is also a quaternary ammonium antibacterial compound.
- an effective amount of alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride may be from about 0.5 to 15% by weight based on the total weight of the disinfectant formulation.
- the disinfectant formulation of the present invention comprises alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride in an amount from about 1.0 to about 10% by weight based on the total weight of the disinfectant formulation, more preferably from about 1.5 to 5.0% by weight, more preferably from about 2.0 to about 4.0% by weight based on the total weight of the disinfectant formulation.
- Alkyl(Ci2 i6) dimethyl benzyl ammonium chloride in any form may be employed in the disinfectant formulation of the present invention. Commercially available forms are available.
- a further component of the disinfectant formulation of the present invention is citric acid.
- Citric acid may be present in an amount from about 0.05 to about 1% by weight based on the total weight of the disinfectant formulation.
- the disinfectant formulation comprises citric acid in an amount from about 0.05 to about 2.0% by weight based on the total weight of the disinfectant
- the disinfectant formulation of the present invention is an aqueous formulation.
- the ingredients are dissolved in water so as to provide a ready-to-use formulation.
- the amount of water employed in an aqueous disinfectant formulation of the present invention may be greater than about 50% by weight based on the total weight of the disinfectant formulation, preferably greater than about 75%, more preferably greater than 85%, more preferably from about 85 to about 98%, more preferably from about 90 to about 96% by weight based on the total weight of the disinfectant formulation.
- the disinfectant formulation of the present invention may also include
- the disinfectant formulations may further comprise conventional disinfectant formulation ingredients. These include acids, surfactants, other disinfecting agents, fragrances, antioxidants, phosphates, colouring agents, or a combination thereof.
- the disinfectant formulation of the present invention further comprises tetrasodium ethylenediamine tetraacetate (EDTA).
- EDTA may be present in an amount from about 0.03 to about 0.07% by weight based on the total weight of the disinfectant formulation, preferably from about 0.04 to about 0.06%, more preferably about 0.05% by weight based on the total weight of the disinfectant formulation.
- the disinfectant formulation of the present invention further comprises alkylpolyglucoside (APG).
- APG may be present in an amount from about 0.05 to about 2.00% by weight based on the total weight of the
- disinfectant formulation preferably from about 0.07 to about 1.03%, more preferably about 1.00% by weight based on the total weight of the disinfectant formulation.
- the disinfectant formulation of the present invention further comprises an acid such as acetic acid, hydrochloric acid, sulphuric acid.
- the acid is acetic acid.
- the acetic acid may be added to the formulation in the form of glacial acetic acid. Acetic acid or the like is added to the formulation in order to obtain the optimum pH.
- glacial acetic acid may be added in an amount necessary to achieve the required pH. Consequently, the disinfectant formulation of the present invention may comprise acetic acid in an amount from about 0.03 to about 0.07% by weight based on the total weight of the disinfectant formulation, preferably from about 0.04 to about 0.06%, more preferably 0.05% by weight based on the total weight of the disinfectant formulation.
- the pH of the disinfectant formulation is from about 2.0 to about 5.0, preferably from about 3.0 to about 4.0, or from about 3.0 to about 3.5, more preferably about 3.5.
- the disinfectant formulation of the present invention is in the form of a sprayable liquid.
- the disinfectant formulation is applied to a substrate surface by way of a hand actuated or pressurised spray delivery device (e.g. a spray gun).
- the disinfectant formulation of the present invention is absorbed onto an absorbent material, preferably a sheet of an absorbent material.
- the absorbent material acts as an applicator device, e.g. a wipe, cloth, cotton bud.
- the disinfectant formulation is then applied to the substrate surface from the absorbent material.
- a wipe comprising a disinfectant formulation of the present invention.
- the disinfectant formulation of the present invention may be suitable for disinfecting a substrate surface against a number of microorganisms including gram positive bacteria or gram negative bacteria such as MRSA (methicillin- resistant staphylococcus aureus), VRE (vanomycin-resistant enter 0 coccus), Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeroginosa,
- MRSA methicillin- resistant staphylococcus aureus
- VRE vanomycin-resistant enter 0 coccus
- Staphylococcus aureus Enterobacter aerogenes
- Pseudomonas aeroginosa gram positive bacteria or gram negative bacteria
- the disinfectant formulation of the present invention is active against MRSA and/or VRE.
- the disinfectant formulation of the present invention provides a Log reduction in the number of bacteria on the substrate surface of at least 6.0 for at least 24 hours.
- the disinfectant formulation of the present invention provides a Log reduction in the number of bacteria on the substrate surface of at least 6.0 for at least 30 days.
- the disinfectant formulation of the present invention provides a Log reduction in the number of bacteria on the substrate surface of at least 7.0 for at least 24 hours.
- the disinfectant formulation of the present invention provides a Log reduction in the number of bacteria on the substrate surface of at least 7.0 for at least 30 days.
- the invention provides the use of a disinfectant formulation of the present invention as described above for disinfecting a substrate surface.
- the disinfectant formulation may be used for destroying microorganisms or a virus and/or inhibiting the growth of microorganisms or a virus on a substrate surface.
- the microorganisms are bacteria.
- the disinfectant formulation of the present invention may be suitable for disinfecting a substrate surface against a number of
- microorganisms including gram positive bacteria or gram negative bacteria such as MRSA (methicillin-resistant staphylococcus aureus), VRE (vanomycin- resistant enter 0 coccus), Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeroginosa, Escherichia coli or a combination thereof, or an influenze virus or a norovirus.
- MRSA methicillin-resistant staphylococcus aureus
- VRE vanomycin- resistant enter 0 coccus
- Staphylococcus aureus Enterobacter aerogenes
- Pseudomonas aeroginosa Escherichia coli or a combination thereof
- an influenze virus or a norovirus preferably, the disinfectant formulation of the present invention is used to disinfect a substrate surface against MRSA and/or VRE.
- the disinfectant formulation of the present invention may be applied to a substrate surface in any environment in which said surface is likely to come into contact with a microorganism or virus.
- environments include healthcare environments such as hospitals, clinics, and nursing homes, schools, sport facilities, hospitality, public transport, agriculture, manufacturing, residential homes, and cruise ships.
- the disinfectant formulation is used in a healthcare environment such as a hospital.
- the substrate surface may be made of any material.
- substrate surfaces on which the disinfectant formulation of the present invention may be applied include wood, metal, laminates, plastics/polymer surfaces, ceramic etc., preferably the substrate surface is a metal such as stainless steel.
- the present invention provides a method of disinfecting a substrate surface comprising applying to said substrate surface a disinfectant formulation comprising 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2 i6) dimethyl benzyl ammonium chloride, and citric acid.
- Such a method may involve any conventional step or steps employed to apply disinfectant to a substrate surface.
- the disinfectant formulation may be applied to the substrate surface by fogging, spraying or wiping.
- a wipe impregnated with disinfectant formulation may be employed.
- the disinfectant formulation is applied so as to form a continuous film on the substrate surface.
- This thin layer allows the disinfectant formulation to remain continuously active, even if the surface becomes contaminated.
- a continuous film of disinfectant formulation on the substrate surface may be achieved by an appropriate spraying technique and/ or wiping the disinfectant formulation on to the substrate surface.
- a fogging process may be employed to form a continuous layer of disinfectant formulation on the substrate surface.
- the surface maybe wiped with a cloth. This has the effect of removing surface debris so that the disinfectant formulation is able to protect the entire treated surface, not just the top layer surface debris.
- the cloth is a non-abrasive cloth.
- the surface is wiped with a cloth using a soap, preferably a mild soap such as a non-ionized soap.
- the surface may be wiped with a non-abrasive cloth using a mild (non-ionized) soap.
- Other ways of improving the effectiveness of the disinfectant formulation include preventing the substrate surface from being wiped with a cloth/wipe after the disinfectant formulation has been applied. Doing so may result in the disinfectant formulation being absorbed into the cloth/wipe, preventing it from forming a protective layer of disinfectant.
- the invention provides a process for preparing a disinfectant formulation comprising combining 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride, and citric acid.
- the process comprises dissolving 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride, and citric acid in water.
- the process involves the steps of (i) dissolving 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride in water to form an aqueous solution; (ii) optionally adding acid until the required pH is achieved, preferably adding glacial acetic acid until the pH of the aqueous solution is about 3.5; and (iii) subsequently adding alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride and citric acid (together with any further ingredients) to the aqueous solution.
- the aqueous solution obtained by step (iii) may be mixed until all the ingredients are fully dissolved. This may involve mixing for about 10 minutes until the ingredients are fully dissolved.
- the further ingredients added in step (iii) are EDTA and APG.
- Example l Disinfectant Formulation of the Invention
- Disinfectant component 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride
- BTC 50E alkly(Ci2 i6) dimethyl benzyl ammonium chloride
- EDTA tetrasodium ethylenediamine tetraacetate
- APG alkylpolyglucoside
- the following testing (Analysis A and B) demonstrates that the disinfectant formulations of the present invention, when applied to stainless steel, are able to significantly reduce the numbers of bacteria inoculated onto the surface. Furthermore, the study shows that the product remains effective for up to 30 days post application.
- the following testing (Analysis C) also demonstrates that individually the component parts of the disinfectant formulations of the present invention: citird acid, 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride and alkly(Ci 2 -i6) dimethyl benzyl ammonium chloride, when applied to stainless steel are not able to significantly reduce the numbers of bacteria inoculated onto the surface.
- the testing performed was based on the Japanese Standard Method JIS Z 2801.
- a treated fabric and an untreated control of the same fabric are inoculated with a known level of organisms, specifically Staphylococcus aureus ATCC 6538 and Escherichia coli ATCC 8739.
- the inoculum is covered by film to prevent the organisms drying out and then incubated at 36°C for 24 hours.
- a set of inoculated untreated coupons is enumerated immediately to determine pre-incubation levels. After 24 hours incubation the treated and untreated coupons are enumerated to determine the number of viable organisms remaining. For the untreated coupons at least 104 cfu/ml must be present. The reduction on the treated surface is calculated in relation to the untreated surface.
- TLB Tryptone Soya Broth
- TSA Tryptone Soya Agar
- a second subculture was prepared, in duplicate, by streaking from the first.
- the secondary (2 0 ) culture was incubated at 36°C for 18- 24 hours.
- a third (3 0 ) subculture was prepared in duplicate, where required, by streaking from the second.
- the tertiary culture was incubated at 36°C for 18- 24 hours.
- the primary, secondary and tertiary cultures were the working cultures.
- the inoculum strength was in the 10 8 cfu/ ml range for MRSA. It was controlled using a spectrophotometer. The inoculum was used within two hours of preparation.
- a disinfectant formulation of the invention according to Example 1 was prepared as detailed above.
- the surfaces were stainless steel grade 304 surfaces 5cm 2 . One side of the surface was marked to facilitate identification of the side exposed to the test procedure.
- the surfaces were cleaned using a non-ionic cleaner and then alcohol, which was allowed to evaporate.
- the product nozzle was adjusted to a light mist setting to give an even coating.
- the surfaces were treated using a side to side motion for 3 minutes to cover the entire surface.
- the surfaces were then wiped using a lint-free tissue to remove excess spray.
- the neutraliser was then left for 30 minutes prior to enumerating.
- Neutraliser Tryptone soya broth 30g/l, polysorbate 20 ioog/1, lecithin 30g/l Test
- the inoculum was covered with 40mm 2 parafilm, which was pressed down so that the inoculum spread under the film, but did not spill over the edge of the coupon.
- the treated coupons and 3 of the untreated coupons were then placed into the incubator at 36°C ⁇ 2°C for 24 hours then enumerated.
- TSC tryptone sodium chloride broth
- Example 1 significantly reduced the number of viable MRSA bacteria within 5 minutes.
- Example 1 significantly reduced the number of viable MRSA and VRE bacteria within 60 minutes.
- Example 1 Surfaces left for 30 days post treatment with Example 1 reduced the number of viable MRSA and VRE bacteria within 60 minutes.
- Example 1 When applied onto stainless steel following the manufacturer's instructions, Example 1 demonstrates antibacterial activity for up to 30 days, killing >99.999% of MRSA within 5 minutes and VRE within 60 minutes.
- TLB Tryptone Soya Broth
- TSA Tryptone Soya Agar
- a second subculture was prepared, in duplicate, by streaking from the first.
- the secondary (2 0 ) culture was incubated at 36°C for 18- 24 hours.
- a third (3 0 ) subculture was prepared in duplicate, where required, by streaking from the second.
- the tertiary culture was incubated at 36°C for 18- 24 hours.
- the primary, secondary and tertiary cultures were the working cultures.
- the inoculum strength was in the 10 8 cfu/ ml range for MRSA. It was controlled using a spectrophotometer. The inoculum was used within two hours of preparation.
- a disinfectant formulation of the invention according to Example 1 was prepared as detailed above.
- the surfaces were stainless steel grade 304 surfaces 5cm 2 .
- One side of the surface was marked to facilitate identification of the side exposed to the test procedure.
- the surfaces were cleaned using a non-ionic cleaner and then alcohol, which was allowed to evaporate.
- the product nozzle was adjusted to a light mist setting to give an even coating.
- the surfaces were treated using a side to side motion for 3 minutes to cover the entire surface.
- the surfaces were then wiped using a lint-free tissue to remove excess spray.
- the neutraliser was then left for 30 minutes prior to enumerating.
- Neutraliser Tryptone soya broth 30g/l, polysorbate 20 ioog/1, lecithin 30g/l
- the inoculum was covered with 40mm 2 parafilm, which was pressed down so that the inoculum spread under the film, but did not spill over the edge of the coupon.
- the treated coupons and 3 of the untreated coupons were then held for a contact time of 5 minutes then enumerated.
- Example 1 After allowing 60 minutes post surface treatment, the disinfectant formulation of Example 1 significantly reduced the number of viable S. aureus, E.coli, and VRE bacteria within 5 minutes.
- Example 1 When applied onto stainless steel following the manufacturer's instructions, the disinfectant formulation of Example 1 demonstrates antibacterial activity for up to 30 days for the organisms tested.
- TLB Tryptone Soya Broth
- TSA Tryptone Soya Agar
- a second subculture was prepared, in duplicate, by streaking from the first.
- the secondary (2 0 ) culture was incubated at 36°C for 18- 24 hours.
- a third (3 0 ) subculture was prepared in duplicate, where required, by streaking from the second.
- the tertiary culture was incubated at 36°C for 18- 24 hours.
- the primary, secondary and tertiary cultures were the working cultures.
- the inoculum strength was in the 10 8 cfu/ ml range for MRSA. It was controlled using a spectrophotometer. The inoculum was used within two hours of preparation.
- the surfaces were stainless steel grade 304 surfaces 5cm 2 .
- One side of the surface was marked to facilitate identification of the side exposed to the test procedure.
- the surfaces were cleaned using a non-ionic cleaner and then alcohol, which was allowed to evaporate.
- the product nozzle was adjusted to a light mist setting to give an even coating.
- the surfaces were treated using a side to side motion for 3 minutes to cover the entire surface.
- the surfaces were then wiped using a lint-free tissue to remove excess spray.
- Neutraliser Tryptone soya broth 30g/l, polysorbate 20 ioog/1, lecithin 30g/l
- the inoculum was covered with 40mm 2 parafilm, which was pressed down so that the inoculum spread under the film, but did not spill over the edge of the coupon.
- the treated coupons and 3 of the untreated coupons were then held for a contact time of 5 minutes then enumerated.
- the neutrialiser was then serially diluted using 0.85% sodium chloride (NaCl).
- Example 1 significantly reduced the number of viable MRSA bacteria within 5 minutes; however, when tested under the same conditions, none of the individual components demonstrated a significant reduction in numbers of bacteria.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a disinfectant formulation, its use for disinfecting a substrate surface and a process for preparing such a disinfectant formulation. The present invention provides a continuous and verifiable disinfectant formulation that achieves a Log reduction in the number of bacteria on the surface of at least 7.0 for 30 days.
Description
Disinfectant Formulation— MS71
The present invention relates to a disinfectant formulation, its use for disinfecting a substrate surface and a process for preparing such a disinfectant formulation. The present invention provides a long lasting continuous disinfectant formulation that achieves a Log reduction in the number of bacteria on the surface of at least 7.0 for 30 days.
Background of the Invention
The World Health Organization has warned that healthcare-associated infections are a leading cause of avoidable morbidity and mortality worldwide. Annual financial losses due to healthcare-associated infections are estimated at approximately€7 billion in Europe alone, including direct cost only, and reflecting 16 million extra days of hospital stay (source: World Health Organization, Healthcare-Associated Infections Fact Sheet).
Considering that "80% of infectious diseases are transferred by touch" (source: Tierno, P., 2001, The Secret Life of Germs), current standard procedures that involve a daily sanitizing response to microbial threats are grossly inadequate in preventing cross- contamination. In healthcare settings patients colonized or infected with pathogens frequently contaminate items in their immediate vicinity with microorganisms, as do healthcare workers who unknowingly contaminate their hands while caring for patients. Indeed, healthcare personnel are sometimes the weakest link in the chain of acquired infection. Despite thorough training and monitoring, the human touch remains a critical disease vector. For example, a study of doctors, nurses, healthcare aides and other workers revealed that out of 2834 observed opportunities for hand washing, the compliance rate was only 48% (source: Pittet, D., 2001 Emerging
Infectious Diseases). In busy healthcare environments cross-contamination, or the inadvertent transfer of a pathogen from one source to another, is therefore a serious risk.
The problem with conventional disinfectant formualtions is that, while they kill microbes, they do not offer any lasting protection, and are thus unable to prevent surfaces from becoming a source of disease transmission when they become re- contaminated - which can happen almost instantly in a busy healthcare environment, when someone touches the surface. Known disinfectant formulations therefore struggle to prevent surface cross-contamination and potential transfer of infectious
diseases. In a busy healthcare environment disinfected surfaces become contaminated almost immediately, e.g. when someone touches the surface. Continuous sanitization of frequently touched surfaces, as well as medical equipment, thus becomes the only means of preventing cross-contamination as health professionals move from patient to patient.
There is therefore a need for a long-lasting disinfectant formulation to address the above problem. The present invention meets this need and solves the problem and thus helps combat the dangerous and growing risk of healthcare-associated infections and other surface-borne, touch-transferable infections. The present invention provides a high grade long -lasting continuous surface disinfectant that will become a key weapon in the fight against this ever-present risk. This is achieved by the disinfectant formulation of the present invention containing a combination of ingredients that unexpectedly provide a synergistic disinfectant effect. In particular, the disinfectant formulation of the present invention provides a disinfectant effect on a substrate surface longer than would have been expected.
The disinfectant formulation of the present invention has been rigorously tested and vigorously proven to give not only immediate, but up to 30-day-long continuous pre- emptive deterrent action that can be verified - breaking an important link in the chain of infection. To be assured the same effectiveness and the same 24/7 protection that the present invention provides, surfaces would need to be disinfected with a conventional disinfectant formulation every time they were touched, even if they had only recently been disinfected.
Summary of Invention
In one aspect the invention provides a disinfectant formulation comprising 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2-i6) dimethyl benzyl ammonium chloride, and citric acid.
In a second aspect the invention provides the use of a disinfectant formulation comprising 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2 i6) dimethyl benzyl ammonium chloride, and citric acid, for disinfecting a substrate surface.
For example, the invention provides a method of disinfecting a substrate surface comprising applying to said substrate surface a disinfectant formulation comprising 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2-i6) dimethyl benzyl ammonium chloride, and citric acid.
In one embodiment of the invention, the disinfectant formulation is used to
disinfectant a substrate surface against a bacteria, and in particular against
Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA),
Escherichia coli {E. coli) or Vancomycin-resistant Enterococcus (VRE).
In a third aspect the invention provides a process for preparing a disinfectant formulation according to the first aspect of the invention comprising combining 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2-i6) dimethyl benzyl ammonium chloride, and citric acid
Detailed Description of the Invention
The term "disinfectant" is used in line with its conventional meaning to refer to a substance that is applied to a non-living object (a substrate surface) to destroy microorganisms, e.g. bacteria, that may be present on that surface. The term is also intended to cover sanitization.
The disinfectant formulation of the invention effectively reduces the number of bacteria inoculated onto a substrate surface. Furthermore, the product remains effective as a disinfectant for at least 30 days after it has been applied to the surface.
In accordance with European Standard EN 13697, an effective reduction is deemed to have been achieved when a formulation demonstrates at least a icH log reduction in the number of microorganisms. That means that less than 1 microorganism in every 10,000 remains on the surface.
One component of the disinfectant formulation of the present invention is 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, which is a quaternary ammonium antibacterial compound. 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride is known to exhibit disinfectant properties and inhibit
microorganisms. However, its antibacterial effect is limited.
The 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride employed in the present invention may be in any form. For example, any commercially available form of it may be employed in the present invention. This includes condensed or diluted forms. 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride is commercially available.
It will be appreciated that an effective amount of 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride is employed in the disinfectant formulation of the present invention. An effective amount may represent from about o.i to about io% by weight based on the total weight of the disinfectant formulation. Preferably, the disinfectant formulation of the present invention comprises 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride in an amount from about o.i to about 5.0% by weight based on the total weight of the disinfectant formulation, more preferably from about 0.5 to about 2.0% by weight, even more preferably from about 0.8 to about 1.0% by weight based on the total weight of the disinfectant formulation.
A further component of the disinfectant formulation of the present invention is alkly(Ci2 i6) dimethyl benzyl ammonium chloride, which is also a quaternary ammonium antibacterial compound.
An effective amount of alkly(Ci2-i6) dimethyl benzyl ammonium chloride may be from about 0.5 to 15% by weight based on the total weight of the disinfectant formulation. Preferably, the disinfectant formulation of the present invention comprises alkly(Ci2-i6) dimethyl benzyl ammonium chloride in an amount from about 1.0 to about 10% by weight based on the total weight of the disinfectant formulation, more preferably from about 1.5 to 5.0% by weight, more preferably from about 2.0 to about 4.0% by weight based on the total weight of the disinfectant formulation.
Alkyl(Ci2 i6) dimethyl benzyl ammonium chloride in any form may be employed in the disinfectant formulation of the present invention. Commercially available forms are available.
A further component of the disinfectant formulation of the present invention is citric acid. Citric acid may be present in an amount from about 0.05 to about 1% by weight based on the total weight of the disinfectant formulation. Preferably, the disinfectant formulation comprises citric acid in an amount from about 0.05
to about 2.0% by weight based on the total weight of the disinfectant
formulation.
In one embodiment the disinfectant formulation of the present invention is an aqueous formulation. The ingredients are dissolved in water so as to provide a ready-to-use formulation. The amount of water employed in an aqueous disinfectant formulation of the present invention may be greater than about 50% by weight based on the total weight of the disinfectant formulation, preferably greater than about 75%, more preferably greater than 85%, more preferably from about 85 to about 98%, more preferably from about 90 to about 96% by weight based on the total weight of the disinfectant formulation.
The disinfectant formulation of the present invention may also include
additional disinfectant formulation excipients. For example, the disinfectant formulations may further comprise conventional disinfectant formulation ingredients. These include acids, surfactants, other disinfecting agents, fragrances, antioxidants, phosphates, colouring agents, or a combination thereof.
In one embodiment the disinfectant formulation of the present invention further comprises tetrasodium ethylenediamine tetraacetate (EDTA). EDTA may be present in an amount from about 0.03 to about 0.07% by weight based on the total weight of the disinfectant formulation, preferably from about 0.04 to about 0.06%, more preferably about 0.05% by weight based on the total weight of the disinfectant formulation.
In one embodiment the disinfectant formulation of the present invention further comprises alkylpolyglucoside (APG). APG may be present in an amount from about 0.05 to about 2.00% by weight based on the total weight of the
disinfectant formulation, preferably from about 0.07 to about 1.03%, more preferably about 1.00% by weight based on the total weight of the disinfectant formulation.
In one embodiment the disinfectant formulation of the present invention further comprises an acid such as acetic acid, hydrochloric acid, sulphuric acid. In a preferred embodiment, the acid is acetic acid. The acetic acid may be added to the formulation in the form of glacial acetic acid. Acetic acid or the like is added
to the formulation in order to obtain the optimum pH. For example, glacial acetic acid may be added in an amount necessary to achieve the required pH. Consequently, the disinfectant formulation of the present invention may comprise acetic acid in an amount from about 0.03 to about 0.07% by weight based on the total weight of the disinfectant formulation, preferably from about 0.04 to about 0.06%, more preferably 0.05% by weight based on the total weight of the disinfectant formulation.
In one embodiment the pH of the disinfectant formulation is from about 2.0 to about 5.0, preferably from about 3.0 to about 4.0, or from about 3.0 to about 3.5, more preferably about 3.5.
In one embodiment the disinfectant formulation of the present invention is in the form of a sprayable liquid. As such, the disinfectant formulation is applied to a substrate surface by way of a hand actuated or pressurised spray delivery device (e.g. a spray gun).
In an alternative embodiment, the disinfectant formulation of the present invention is absorbed onto an absorbent material, preferably a sheet of an absorbent material. The absorbent material acts as an applicator device, e.g. a wipe, cloth, cotton bud. The disinfectant formulation is then applied to the substrate surface from the absorbent material. Accordingly, in one embodiment is provided a wipe comprising a disinfectant formulation of the present invention.
The disinfectant formulation of the present invention may be suitable for disinfecting a substrate surface against a number of microorganisms including gram positive bacteria or gram negative bacteria such as MRSA (methicillin- resistant staphylococcus aureus), VRE (vanomycin-resistant enter 0 coccus), Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeroginosa,
Escherichia coli , and combinations thereof, or an influenza virus or a norovirus. Preferably, the disinfectant formulation of the present invention is active against MRSA and/or VRE.
In an embodiment the disinfectant formulation of the present invention provides a Log reduction in the number of bacteria on the substrate surface of at least 6.0 for at least 24 hours. In an embodiment the disinfectant formulation of the present invention provides a Log reduction in the number of bacteria on the substrate surface of at least 6.0 for at least 30 days.
In an embodiment the disinfectant formulation of the present invention provides a Log reduction in the number of bacteria on the substrate surface of at least 7.0 for at least 24 hours.
In an embodiment the disinfectant formulation of the present invention provides a Log reduction in the number of bacteria on the substrate surface of at least 7.0 for at least 30 days.
In a second aspect the invention provides the use of a disinfectant formulation of the present invention as described above for disinfecting a substrate surface. In this respect, the disinfectant formulation may be used for destroying microorganisms or a virus and/or inhibiting the growth of microorganisms or a virus on a substrate surface. Commonly, the microorganisms are bacteria.
As stated previously, the disinfectant formulation of the present invention may be suitable for disinfecting a substrate surface against a number of
microorganisms including gram positive bacteria or gram negative bacteria such as MRSA (methicillin-resistant staphylococcus aureus), VRE (vanomycin- resistant enter 0 coccus), Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeroginosa, Escherichia coli or a combination thereof, or an influenze virus or a norovirus. Preferably, the disinfectant formulation of the present invention is used to disinfect a substrate surface against MRSA and/or VRE.
The disinfectant formulation of the present invention may be applied to a substrate surface in any environment in which said surface is likely to come into contact with a microorganism or virus. Such environments include healthcare
environments such as hospitals, clinics, and nursing homes, schools, sport facilities, hospitality, public transport, agriculture, manufacturing, residential homes, and cruise ships. Preferably, the disinfectant formulation is used in a healthcare environment such as a hospital.
The substrate surface may be made of any material. In particular, substrate surfaces on which the disinfectant formulation of the present invention may be applied include wood, metal, laminates, plastics/polymer surfaces, ceramic etc., preferably the substrate surface is a metal such as stainless steel.
For example, the present invention provides a method of disinfecting a substrate surface comprising applying to said substrate surface a disinfectant formulation comprising 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2 i6) dimethyl benzyl ammonium chloride, and citric acid.
Such a method may involve any conventional step or steps employed to apply disinfectant to a substrate surface. For example, the disinfectant formulation may be applied to the substrate surface by fogging, spraying or wiping. When applying the disinfectant formulation with a wipe, a wipe impregnated with disinfectant formulation may be employed.
To achieve the most effective results, the disinfectant formulation is applied so as to form a continuous film on the substrate surface. This allows a thin film to form on the surface. This thin layer allows the disinfectant formulation to remain continuously active, even if the surface becomes contaminated. A continuous film of disinfectant formulation on the substrate surface may be achieved by an appropriate spraying technique and/ or wiping the disinfectant formulation on to the substrate surface. Alternatively, a fogging process may be employed to form a continuous layer of disinfectant formulation on the substrate surface.
In order to improve the effectiveness of the disinfectant formulation, before applying the disinfectant formulation to the substrate surface, the surface maybe wiped with a cloth. This has the effect of removing surface debris so that the disinfectant
formulation is able to protect the entire treated surface, not just the top layer surface debris.
In one embodiment, the cloth is a non-abrasive cloth.
In one embodiment, the surface is wiped with a cloth using a soap, preferably a mild soap such as a non-ionized soap.
Accordingly, before applying the disinfectant formulation to the substrate surface, the surface may be wiped with a non-abrasive cloth using a mild (non-ionized) soap.
Other ways of improving the effectiveness of the disinfectant formulation include preventing the substrate surface from being wiped with a cloth/wipe after the disinfectant formulation has been applied. Doing so may result in the disinfectant formulation being absorbed into the cloth/wipe, preventing it from forming a protective layer of disinfectant.
In a third aspect the invention provides a process for preparing a disinfectant formulation comprising combining 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2-i6) dimethyl benzyl ammonium chloride, and citric acid.
In one embodiment the process comprises dissolving 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2-i6) dimethyl benzyl ammonium chloride, and citric acid in water.
In one embodiment the process involves the steps of (i) dissolving 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride in water to form an aqueous solution; (ii) optionally adding acid until the required pH is achieved, preferably adding glacial acetic acid until the pH of the aqueous solution is about 3.5; and (iii) subsequently adding alkly(Ci2-i6) dimethyl benzyl ammonium chloride and citric acid (together with any further ingredients) to the aqueous solution.
The aqueous solution obtained by step (iii) may be mixed until all the ingredients are fully dissolved. This may involve mixing for about 10 minutes until the ingredients are fully dissolved.
In one embodiment the further ingredients added in step (iii) are EDTA and APG.
Certain embodiments of the invention will now be described with reference to the following examples which are intended for the purpose of illustration only and are not intended to limit the scope of generality hereinbefore described.
Examples
Example l: Disinfectant Formulation of the Invention
Disinfectant component: 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride
BTC 50E: alkly(Ci2 i6) dimethyl benzyl ammonium chloride
EDTA: tetrasodium ethylenediamine tetraacetate
APG: alkylpolyglucoside
Process for Preparation
1. Dissolve the disinfectant component in deionised water.
2. Add Glacial Acetic Acid if necessary until pH is around 3.5.
3. Add following ingredient in order with agitation : BTC 50E, EDTA , Citric Acid , and APG
4. Mix for 10 minutes until fully dissolved. Testing of Antibacterial Activity
The following testing (Analysis A and B) demonstrates that the disinfectant formulations of the present invention, when applied to stainless steel, are able to
significantly reduce the numbers of bacteria inoculated onto the surface. Furthermore, the study shows that the product remains effective for up to 30 days post application. The following testing (Analysis C) also demonstrates that individually the component parts of the disinfectant formulations of the present invention: citird acid, 3- (trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride and alkly(Ci2-i6) dimethyl benzyl ammonium chloride, when applied to stainless steel are not able to significantly reduce the numbers of bacteria inoculated onto the surface.
Method Overview
The testing performed was based on the Japanese Standard Method JIS Z 2801. As standard for this method a treated fabric and an untreated control of the same fabric are inoculated with a known level of organisms, specifically Staphylococcus aureus ATCC 6538 and Escherichia coli ATCC 8739. The inoculum is covered by film to prevent the organisms drying out and then incubated at 36°C for 24 hours. A set of inoculated untreated coupons is enumerated immediately to determine pre-incubation levels. After 24 hours incubation the treated and untreated coupons are enumerated to determine the number of viable organisms remaining. For the untreated coupons at least 104 cfu/ml must be present. The reduction on the treated surface is calculated in relation to the untreated surface.
Acceptance criteria: log reduction≥2 Analysis A
The above method was selected although the product is applied rather than pre-treated as there is no specific standard method for this type of product. Deviations were performed to enable specific claims required:
1. The study was performed using MRSA and VRE and not the standard organisms since compliance to the standard was not required.
2. Stainless steel coupons were used as the base material and then treated with product to form the treated coupon; untreated stainless steel was used as the uninoculated coupon.
3. The stainless steel was treated as below and then held for 30 days prior to performing the test in order to prove that the product remained effective over this time frame.
4. A contact time of 60 minutes was tested in addition to the 24 hours specified in the standard.
5. For MRSA a contact time of 5 minutes was also tested.
6. A high inoculum was used in order to determine a log 3 reduction rather than the log 2 required by the standard.
7. The neutraliser used was validated to prove that it was effective.
Preparation of Test Organisms
Identification of the bacterial strain used:
Preparation of Bacteria
A bead was removed from the cryovial, and placed in 10ml Tryptone Soya Broth (TSB); this was the stock culture. The stock culture was allowed to sit at room temperature for a few of minutes before use.
Each stock culture was streaked onto Tryptone Soya Agar (TSA). Bacteria were incubated at 36°C for 18-24 hours, then checked for purity and viability. (48 or 72 hours was acceptable providing the culture has been incubated for the entire period).
Cultures were re-incubated for a further 24 hours to confirm purity.
A second subculture was prepared, in duplicate, by streaking from the first.
The secondary (20) culture was incubated at 36°C for 18- 24 hours.
A third (30) subculture was prepared in duplicate, where required, by streaking from the second.
The tertiary culture was incubated at 36°C for 18- 24 hours. The primary, secondary and tertiary cultures were the working cultures.
The inoculum strength was in the 108 cfu/ ml range for MRSA. It was controlled using a spectrophotometer. The inoculum was used within two hours of preparation.
Preparation of Disinfectant Solutions
A disinfectant formulation of the invention according to Example 1 was prepared as detailed above.
The surfaces were stainless steel grade 304 surfaces 5cm2.
One side of the surface was marked to facilitate identification of the side exposed to the test procedure.
The surfaces were cleaned using a non-ionic cleaner and then alcohol, which was allowed to evaporate.
When the surfaces were completely dry the product nozzle was adjusted to a light mist setting to give an even coating. The surfaces were treated using a side to side motion for 3 minutes to cover the entire surface. The surfaces were then wiped using a lint-free tissue to remove excess spray.
Once treated the surfaces were stored for 60 minutes prior to starting the test, this was the o day test; or for 30 days, this was the 30 day test.
Neutraliser Validation
In order to prove that the neutraliser was valid a treated uninoculated surface was added to neutraliser, the recovery process performed as for the inoculated coupons and then MRSA was added to achieve 10-ioocfu/ ml.
The neutraliser was then left for 30 minutes prior to enumerating.
Acceptance criteria:≥50% of the inoculum.
Neutraliser Tryptone soya broth 30g/l, polysorbate 20 ioog/1, lecithin 30g/l Test
9 stainless steel coupons were used to perform the test. 3 were treated with the product as above. 6 were left untreated to be used as control coupons.
Each coupon, treated and untreated, was inoculated with 0.4ml of the inoculum.
The inoculum was covered with 40mm2 parafilm, which was pressed down so that the inoculum spread under the film, but did not spill over the edge of the coupon.
The treated coupons and 3 of the untreated coupons were then placed into the incubator at 36°C ±2°C for 24 hours then enumerated.
The remaining three untreated coupons were enumerated immediately to determine number of viable bacteria.
In order to enumerate the coupons each was added to a sterile bag, ensuring the inoculum did not spill.
10ml neutraliser was added to each bag and the coupon massaged by hand for 30 seconds.
The neutraliser was then serially diluted using tryptone sodium chloride broth (TSC). lml duplicate pour plates were prepared and incubated for 48 hours at 36°C.
After incubation plates were counted.
Calculation of Results
Calculations were performed to 2 significant figures, using the dilution with an average count of 30-300cfu where possible.
For each coupon the cfu/coupon was calculated:
Untreated Product, Immediate Neutralisation
Calculate cfu/coupon for each of the three coupons.
Determine the average cfu /coupon.
Calculate the log[cfu/coupon] for each of the three control coupons.
Determine the average.
Acceptance criteria: Log maximum " Log minimum / Log average = < 0.2
Untreated Product, 24 hour incubation
Calculate cfu/coupon for each of the three coupons
Determine the average cfu /coupon (B).
Treated product, 24 Hour Incubation (Test)
Calculate cfu/coupon for each of the three coupons
Determine the average.
Calculate the average cfu /coupon (C)
Calculate Antimicrobial activity :
R = (log [B/C]),
Where
R: value of antimicrobial activity
B: average cfu/ml on the untreated coupon after 24 hours C: average cfu/ml on the treated coupon after 24 hours (test)
Pass criteria: R≥ 2.0
Results Summary Table
Organism Coupon Treatment Time Contact Time Log Percentage
Reduction Reduction
MRSA 0 Day 5 mins >7-i >99·999%
MRSA 0 Day 60 mins 7.2 >99·999%
MRSA 0 Day 24 hrs >6.8 >99·999%
MRSA 30 Day 60 mins >7.o >99·999%
VRE 0 Day 60 mins >7.o >99·999%
VRE 0 Day 24 hrs >6.6 >99·999%
VRE 30 Day 60 mins >7.0 >99·999%
VRE 30 Day 24 hrs >6.6 >99·999%
Discussion:
All validation tests performed met the acceptance criteria. After allowing 60 minutes post surface treatment, Example 1 significantly reduced the number of viable MRSA bacteria within 5 minutes.
After allowing 60 minutes post surface treatment, Example 1 significantly reduced the number of viable MRSA and VRE bacteria within 60 minutes.
Surfaces left for 30 days post treatment with Example 1 reduced the number of viable MRSA and VRE bacteria within 60 minutes.
Conclusion:
When applied onto stainless steel following the manufacturer's instructions, Example 1 demonstrates antibacterial activity for up to 30 days, killing >99.999% of MRSA within 5 minutes and VRE within 60 minutes.
Deviations:
None
Analysis B
The above method (see method overview) was selected although the product is applied rather than pre-treated as there is no specific standard method for this type of product. Deviations were performed to enable specific claims required:
1. The study was performed using MRSA, VRE, Escherichia coli and
Staphylococcus aureus.
2. Stainless steel coupons were used as the base material and then treated with product to form the treated coupon; untreated stainless steel was used as the uninoculated coupon.
3. The stainless steel was treated as below and then held for 30 days prior to performing the test in order to prove that the product remained effective over this time frame.
4. A contact time of 5 minutes was tested.
5. A high inoculum was used in order to determine a log 3 reduction rather than the log 2 required by the standard.
6. The neutraliser used was validated to prove that it was effective.
Preparation of Test Organisms
Identification of the bacterial strain used:
Preparation of Bacteria
A bead was removed from the cryovial, and placed in 10ml Tryptone Soya Broth (TSB); this was the stock culture. The stock culture was allowed to sit at room temperature for a few of minutes before use.
Each stock culture was streaked onto Tryptone Soya Agar (TSA). Bacteria were incubated at 36°C for 18-24 hours, then checked for purity and viability. (48 or 72 hours was acceptable providing the culture has been incubated for the entire period). Cultures were re-incubated for a further 24 hours to confirm purity.
A second subculture was prepared, in duplicate, by streaking from the first.
The secondary (20) culture was incubated at 36°C for 18- 24 hours.
A third (30) subculture was prepared in duplicate, where required, by streaking from the second.
The tertiary culture was incubated at 36°C for 18- 24 hours. The primary, secondary and tertiary cultures were the working cultures.
The inoculum strength was in the 108 cfu/ ml range for MRSA. It was controlled using a spectrophotometer. The inoculum was used within two hours of preparation.
Preparation of Disinfectant Solutions
A disinfectant formulation of the invention according to Example 1 was prepared as detailed above.
The surfaces were stainless steel grade 304 surfaces 5cm2.
One side of the surface was marked to facilitate identification of the side exposed to the test procedure.
The surfaces were cleaned using a non-ionic cleaner and then alcohol, which was allowed to evaporate.
When the surfaces were completely dry the product nozzle was adjusted to a light mist setting to give an even coating. The surfaces were treated using a side to side motion for 3 minutes to cover the entire surface. The surfaces were then wiped using a lint-free tissue to remove excess spray.
Once treated the surfaces were stored for 30 days. Neutraliser Validation
In order to prove that the neutraliser was valid a treated uninoculated surface was added to neutraliser, the recovery process performed as for the inoculated coupons and then MRSA was added to achieve 10-ioocfu/ml.
The neutraliser was then left for 30 minutes prior to enumerating.
Acceptance criteria:≥50% of the inoculum.
Neutraliser Tryptone soya broth 30g/l, polysorbate 20 ioog/1, lecithin 30g/l
Test
9 stainless steel coupons were used to perform the test. 3 were treated with the product as above. 6 were left untreated to be used as control coupons.
Each coupon, treated and untreated, was inoculated with 0.4ml of the inoculum.
The inoculum was covered with 40mm2 parafilm, which was pressed down so that the inoculum spread under the film, but did not spill over the edge of the coupon.
The treated coupons and 3 of the untreated coupons were then held for a contact time of 5 minutes then enumerated.
The remaining three untreated coupons were enumerated immediately to determine number of viable bacteria.
In order to enumerate the coupons each was added to a sterile bag, ensuring the inoculum did not spill.
10ml neutraliser was added to each bag and the coupon massaged by hand for 30 seconds.
The neutraliser was then serially diluted using tryptone sodium chloride broth (TSC). iml duplicate pour plates were prepared and incubated for 48 hours at 36°C.
After incubation plates were counted.
Calculation of Results
Calculations were performed to 2 significant figures, using the dilution with an averagi count of 30-300cfu where possible.
For each coupon the cfu/coupon was calculated:
Untreated Product, Immediate Neutralisation
Calculate cfu/coupon for each of the three coupons.
Determine the average cfu /coupon.
Calculate the log[cfu/coupon] for each of the three control coupons.
Determine the average.
Acceptance criteria: Log maximum " Log minimum / Log average = < 0.2
Untreated Product, 24 hour incubation
Calculate cfu/coupon for each of the three coupons
Determine the average cfu /coupon (B).
Treated product, 24 Hour Incubation (Test)
Calculate cfu/coupon for each of the three coupons
Determine the average.
Calculate the average cfu /coupon (C)
Calculate Antimicrobial activity :
R = (log [B/C]),
Where
R: value of antimicrobial activity
B: average cfu/ml on the untreated coupon after 24 hours C: average cfu/ml on the treated coupon after 24 hours (test)
Pass criteria: R≥ 2.0
Results Summary Table
Discussion:
All validation tests performed met the acceptance criteria.
After allowing 60 minutes post surface treatment, the disinfectant formulation of Example 1 significantly reduced the number of viable S. aureus, E.coli, and VRE bacteria within 5 minutes.
Surfaces left for 30 days post treatment with the disinfectant formulation of Example 1 reduced the number of viable S. aureus, E.coli, and VRE bacteria within 5 minutes.
Conclusion:
When applied onto stainless steel following the manufacturer's instructions, the disinfectant formulation of Example 1 demonstrates antibacterial activity for up to 30 days for the organisms tested.
Deviations:
None
Analysis C
The above method (see method overview) was selected although the product is applied rather than pre-treated as there is no specific standard method for this type of product. Deviations were performed to enable specific claims required:
1. The study was performed using MRSA.
2. Stainless steel coupons were used as the base material and then treated with product to form the treated coupon; untreated stainless steel was used as the uninoculated coupon.
3. The stainless steel was treated as below and then tested immediately.
4. A contact time of 5 minutes was tested.
5. The neutraliser used was validated to prove that it was effective. Preparation of Test Organisms
Identification of the bacterial strain used:
Preparation of Bacteria
A bead was removed from the cryovial, and placed in 10ml Tryptone Soya Broth (TSB); this was the stock culture. The stock culture was allowed to sit at room temperature for a few of minutes before use.
Each stock culture was streaked onto Tryptone Soya Agar (TSA). Bacteria were incubated at 36°C for 18-24 hours, then checked for purity and viability. (48 or 72 hours was acceptable providing the culture has been incubated for the entire period).
Cultures were re-incubated for a further 24 hours to confirm purity.
A second subculture was prepared, in duplicate, by streaking from the first.
The secondary (20) culture was incubated at 36°C for 18- 24 hours.
A third (30) subculture was prepared in duplicate, where required, by streaking from the second.
The tertiary culture was incubated at 36°C for 18- 24 hours. The primary, secondary and tertiary cultures were the working cultures.
The inoculum strength was in the 108 cfu/ ml range for MRSA. It was controlled using a spectrophotometer. The inoculum was used within two hours of preparation.
Tested Solutions
The following solutions were tested:
1. 0.01% solution of citric acid
2. 3% solution of alkly(Ci2 i6) dimethyl benzyl ammonium chloride
3. 0.9% solution of 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium
chloride (in deionised water)
The surfaces were stainless steel grade 304 surfaces 5cm2.
One side of the surface was marked to facilitate identification of the side exposed to the test procedure.
The surfaces were cleaned using a non-ionic cleaner and then alcohol, which was allowed to evaporate.
When the surfaces were completely dry the product nozzle was adjusted to a light mist setting to give an even coating. The surfaces were treated using a side to side motion for 3 minutes to cover the entire surface. The surfaces were then wiped using a lint-free tissue to remove excess spray.
Once treated the surfaces were stored for 30 days.
Neutraliser Tryptone soya broth 30g/l, polysorbate 20 ioog/1, lecithin 30g/l
Test
9 stainless steel coupons were used to perform the test. 3 were treated with the product as above. 6 were left untreated to be used as control coupons.
Each coupon, treated and untreated, was inoculated with 0.4ml of the inoculum.
The inoculum was covered with 40mm2 parafilm, which was pressed down so that the inoculum spread under the film, but did not spill over the edge of the coupon.
The treated coupons and 3 of the untreated coupons were then held for a contact time of 5 minutes then enumerated.
The remaining three untreated coupons were enumerated immediately to determine number of viable bacteria.
In order to enumerate the coupons each was added to a sterile bag, ensuring the inoculum did not spill.
10ml neutraliser was added to each bag and the coupon massaged by hand for 30 seconds.
The neutrialiser was then serially diluted using 0.85% sodium chloride (NaCl).
lml duplicate pour plates were prepared and incubated for 48 hours at 36°C.
After incubation plates were counted.
Calculation of Results
Calculations were performed to 2 significant figures, using the dilution with an average count of 30-300cfu where possible.
For each coupon the cfu/coupon was calculated:
Untreated Product, Immediate Neutralisation
Calculate cfu/coupon for each of the three coupons.
Determine the average cfu /coupon.
Calculate the log[cfu/coupon] for each of the three control coupons.
Determine the average.
Acceptance criteria: Log maximum " Log minimum / Log average = < 0.2
Untreated Product, 24 hour incubation
Calculate cfu/coupon for each of the three coupons
Determine the average cfu /coupon (B).
Treated product, 24 Hour Incubation (Test)
Calculate cfu/coupon for each of the three coupons
Determine the average.
Calculate the average cfu /coupon (C)
Calculate Antimicrobial activity :
R = (log [B/C]),
Where
R: value of antimicrobial activity
B: average cfu/ml on the untreated coupon after 24 hours C: average cfu/ml on the treated coupon after 24 hours (test)
Pass criteria: R≥ 2.0
Results Summary Table
Product Organism Coupon Contact Log Percentage
Treatment Time Reduction Reduction Time
0.01% citric acid MRSA 0 Day 5 minutes 0.5 11%
3% alkly(C12-l6) MRSA 0 Day 5 minutes 1.9 98.7% dimethyl benzyl
ammonium
chloride
0.9% 3- MRSA 0 Day 5 minutes <0.1 <1%
(trimethoxysilyl)
propyl dimethyl
octadecyl
ammonium
chloride
Example 1 MRSA 0 Day 5 minutes >7.0 >99·999
Discussion:
All validation tests performed met the acceptance criteria. The disinfectant formulation of Example 1 significantly reduced the number of viable MRSA bacteria within 5 minutes; however, when tested under the same conditions, none of the individual components demonstrated a significant reduction in numbers of bacteria. Conclusion:
Individually, the components of the disinfectant formulation of Example 1 are unable to demonstrate significant antimicrobial activity against MRSA when applied onto stainless steel following the manufacturer's instructions. Deviations:
None.
Claims
1. A disinfectant formulation comprising 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2-i6) dimethyl benzyl ammonium chloride, and citric acid.
2. The disinfectant formulation of claim 1, wherein the disinfectant formulation is an aqueous disinfectant formulation further comprising water.
3. The disinfectant formulation of claim 2, wherein the water is present in an amount of at least 50% by weight based on the total weight of the disinfectant formulation.
4. The disinfectant formulation of any one of the preceding claims, wherein the formulation has a pH from about 2 to about 5.
5. The disinfectant formulation of claim 4, wherein the formulation has a pH of about 3.5.
6. The disinfectant formulation of any one of the preceding claims, further comprising one or more additional disinfectant formulation excipients.
7. The disinfectant formulation of claim 6, wherein the additional disinfectant formulation excipient(s) is selected from the group consisting of acids, surfactants, additional disinfecting agents, fragrances, antioxidants, phosphates and colouring agent.
8. The disinfectant formulation of claim 6 or claim 7, wherein the additional disinfectant formulation excipinets are EDTA, alkylpolyglucoside and acetic acid.
9. Use of a disinfectant formulation as defined in any one of claims 1 to 8, for disinfecting a substrate surface.
10. The use of claim 9, for destroying microorganisms or a virus, or inhibiting the growth of microorganisms or a virus on the substrate surface.
11. The use of claim 10, wherein the microorganism is a bacteria.
12. The use of claim 11, wherein the bacteria is MRSA or VSE.
13. The use of any one of claims 9 to 12, wherein the substrate surface is stainless steel.
14. A method of disinfecting a substrate surface comprising the step of applying a disinfectant formulation as defined in any one of claims 1 to 8 to said surface.
15. A process for preparing a disinfectant formulation as defined in any one of claims 1 to 8 comprising combining 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2-i6) dimethyl benzyl ammonium chloride, and citric acid.
16. The process of claim 15, wherein 3-(trimethoxysilyl)propyl dimethyl octadecyl ammonium chloride, alkly(Ci2-i6) dimethyl benzyl ammonium chloride, and citric acid are combined by dissolving in water.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1217281.3A GB201217281D0 (en) | 2012-09-27 | 2012-09-27 | Disinfectant formulation - MS71 |
| GB1217281.3 | 2012-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014049370A1 true WO2014049370A1 (en) | 2014-04-03 |
Family
ID=47225280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2013/052527 WO2014049370A1 (en) | 2012-09-27 | 2013-09-27 | Disinfectant formulation - ms71 |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201217281D0 (en) |
| WO (1) | WO2014049370A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018236977A1 (en) * | 2017-06-23 | 2018-12-27 | Allied Bioscience, Inc. | Infection control method and system |
| US20220192192A1 (en) * | 2012-11-05 | 2022-06-23 | Monsanto Technology Llc | Low volatility herbicidal compositions |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0339957A2 (en) * | 1988-04-28 | 1989-11-02 | Dow Corning Corporation | A synergistic antimicrobial composition |
| WO1992014810A1 (en) * | 1991-02-15 | 1992-09-03 | S.C. Johnson & Son, Inc. | Production of stable aqueous hydrolyzable organosilane solutions |
| WO1997042818A1 (en) * | 1996-05-11 | 1997-11-20 | Applied Chemicals Limited | Acid food industry sanitizer composition containing a biocidally active surfactant |
| WO2005044966A1 (en) * | 2003-11-01 | 2005-05-19 | Reckitt Benckiser Inc | Cleaning compositions |
| WO2006086271A2 (en) * | 2005-02-07 | 2006-08-17 | Jacques Elfersy | Methods and compositions for biocidal treatments |
| WO2007099144A2 (en) * | 2006-03-02 | 2007-09-07 | Vitec Speciality Chemicals Limited | Water-stabilised antimicrobial organosilane products, compositions, and methods for using the same |
| WO2009030641A1 (en) * | 2007-09-06 | 2009-03-12 | Vitec Speciality Chemicals Limited | Water-stabilized antimicrobial organosilane compositions, and methods for using the same |
-
2012
- 2012-09-27 GB GBGB1217281.3A patent/GB201217281D0/en not_active Ceased
-
2013
- 2013-09-27 WO PCT/GB2013/052527 patent/WO2014049370A1/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0339957A2 (en) * | 1988-04-28 | 1989-11-02 | Dow Corning Corporation | A synergistic antimicrobial composition |
| WO1992014810A1 (en) * | 1991-02-15 | 1992-09-03 | S.C. Johnson & Son, Inc. | Production of stable aqueous hydrolyzable organosilane solutions |
| WO1997042818A1 (en) * | 1996-05-11 | 1997-11-20 | Applied Chemicals Limited | Acid food industry sanitizer composition containing a biocidally active surfactant |
| WO2005044966A1 (en) * | 2003-11-01 | 2005-05-19 | Reckitt Benckiser Inc | Cleaning compositions |
| WO2006086271A2 (en) * | 2005-02-07 | 2006-08-17 | Jacques Elfersy | Methods and compositions for biocidal treatments |
| WO2007099144A2 (en) * | 2006-03-02 | 2007-09-07 | Vitec Speciality Chemicals Limited | Water-stabilised antimicrobial organosilane products, compositions, and methods for using the same |
| WO2009030641A1 (en) * | 2007-09-06 | 2009-03-12 | Vitec Speciality Chemicals Limited | Water-stabilized antimicrobial organosilane compositions, and methods for using the same |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220192192A1 (en) * | 2012-11-05 | 2022-06-23 | Monsanto Technology Llc | Low volatility herbicidal compositions |
| WO2018236977A1 (en) * | 2017-06-23 | 2018-12-27 | Allied Bioscience, Inc. | Infection control method and system |
| US10456493B2 (en) | 2017-06-23 | 2019-10-29 | Allied Bioscience, Inc. | Infection control apparatus |
| US11160893B2 (en) | 2017-06-23 | 2021-11-02 | Allied Bioscience, Inc. | Infection control method and system |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201217281D0 (en) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11044914B2 (en) | Antimicrobial sanitizer compositions and their use | |
| US10244758B2 (en) | Compositions comprising a germinant and an antimicrobial agent | |
| US20140011766A1 (en) | Antimicrobial compositions and methods | |
| CA2884060C (en) | A prolonged disinfectant composition for non-biological surfaces comprising silver ion water and aloe vera | |
| JP2009519220A (en) | Pathogen-control drug | |
| JP2006519841A (en) | Surface disinfecting composition with improved antibacterial performance | |
| EP2348842A2 (en) | Use of cationic surfactants as sporicidal agents | |
| WO2006097758A2 (en) | Antimicrobial composition | |
| CN102614113A (en) | Compound washing-free disinfection gel | |
| CN101466265A (en) | Alcohol-containing antimicrobial compositions having improved efficacy | |
| WO2014049370A1 (en) | Disinfectant formulation - ms71 | |
| CN101460053A (en) | Methods and articles having a high antiviral and antibacterial efficacy | |
| US11337423B1 (en) | Candida auris disinfectant | |
| JPH07252105A (en) | Liquid disinfectant | |
| US20180086694A1 (en) | Disinfecting compositions having improved antimicrobial efficacy | |
| CN104490936A (en) | Skin disinfectant | |
| Santa Packyanathan et al. | Comparison of the Antimicrobial effect of Ethanolic Hand Sanitizers and other Hand Disinfection Methods in Hospitals | |
| Packyanathan et al. | Comparison of the antimicrobial effect of ethanolic hand Sanitizers and other hand disinfection methods in hospitals | |
| CN108064847A (en) | Bactericidal composition with improved antimicrobial efficacy | |
| Sˇuljagic | A pragmatic approach to judicious selection and proper use of disinfectant and antiseptic agents in healthcare settings | |
| RU2413496C2 (en) | Alcohol-free scrub-up composition and method of using thereof | |
| JP2023529385A (en) | Composition | |
| KR20230105067A (en) | Disinfectant composition with excellent sterilization power and sterilization rate | |
| RU2317110C1 (en) | Cutaneous antiseptic agent "septusin-antisept" | |
| WO2015038606A1 (en) | Antimicrobial compositions and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13771201 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 13-082015 DATED 13/08/2015) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13771201 Country of ref document: EP Kind code of ref document: A1 |